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Functional characterizationRecent advances in sequencing and genomic technologies have resulted in the discovery of thousands of previ-
ously unannotated long noncoding RNAs (lncRNAs). However, their function in the cardiovascular system
remains elusive. Here we review and discuss considerations for cardiovascular lncRNA discovery, annotation
and functional characterization. Although we primarily focus on the heart, the proposed pipeline should foster
functional and mechanistic exploration of these transcripts in various cardiovascular pathologies. Moreover,
these insights could ultimately lead to novel therapeutic approaches targeting lncRNAs for the amelioration of
cardiovascular diseases including heart failure.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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proaches for patients suffering with HF include for instance inhibitors
of the renin angiotensin system and beta adrenergic receptor antago-
nists, which target neurohormonal signaling pathways [2]. Although
these therapies have improved the survival of HF patients, they fail
to reverse or even halt the pathogenesis of heart failure. In light of this
unmet clinical need, the elucidation of the precise molecular mecha-
nisms controlling pathological remodeling and identiﬁcation of novel
therapeutic targets are required with the promise of identifying
alternative approaches to prevent this prevalent and deadly disease.
In the adult heart, stress-dependent neurohormonal and hemody-
namic signals induce a pathological remodeling process associated
with cardiomyocyte (CM) hypertrophy and ﬁbrosis, which leads to
further myocyte death during the chronic phase of the response [3].
These combined processes culminate to induce contractile and structural
failure, the hallmarks of HF. At the cellular and molecular levels, these
neurohormonal and hemodynamic stressors activate a network of
integrated signal transduction cascades that converge on a set of core
cardiac transcription factors (TFs) [4]. These evolutionary conserved
TFs (e.g. GATA4, NKX2.5, and MEF2) interact in a combinatorial manner
at target cis-regulatory sequences (promoters and enhancers) to elicit
speciﬁc gene expression programs [5]. However, the notion that the
gene regulatory networks (GRNs) activated by cardiac stressors are pri-
marily protein-based regulatory systems has proved to be premature.
With the advent of ultra high throughput sequencing technologies, a
number of important studies have demonstrated that these GRNs are
under the control of amyriad of interleaved networks of regulatory non-
coding RNAs (ncRNAs) [6]. These ncRNAs control numerous aspects of
pathological GRN activity via a diverse array of regulatory mechanisms.
Currently, the best characterized ncRNAs in the heart are themicroRNAs
(miRNAs). These small regulatory ncRNAs contribute to ﬁne-tune the
activity of the cardiac GRN post transcriptionally via targeting protein-
coding transcripts for degradation, thereby implicating miRNAs as
important stress-dependent modulators of the physio-pathological re-
sponse in the damaged heart. In addition to miRNAs, recent screens
have identiﬁed other regulatory classes of ncRNAs, namely long noncod-
ing RNAs (lncRNAs) [7]. In the present review, we provide the reader
with suggestion to identify and functionally characterize novel lncRNAs
in the cardiovascular system.
2. Long noncoding RNAs
The broad term lncRNA is an operational term that refers to tran-
scripts greater than 200 nucleotides in length, which, in addition, do
not apparently encode a protein sequence [8]. This size threshold is a
convenient but arbitrary one that excludes most known classes of
small regulatory and infrastructural RNAs, including tRNAs, piRNAs
and miRNAs. Importantly, although these transcripts are referred to as
noncoding, a few lncRNAs have been found to encode micropeptides
[9]. Most lncRNAs are expressed at relatively lower levels when com-
pared to messenger RNAs (mRNAs), demonstrate a more restricted
expression pattern and are typically found to be associatedwith ubiqui-
tously expressed chromatin modifying complexes or splice factors [8].
In contrast, those that are expressed at levels comparable to mRNAs
appear to be implicated as structural scaffolds for specialized nuclear
domains. Some lncRNAs are also enriched in the cytoplasm, suggesting
roles in regulating cellular functions in this compartment. Collectively,
these diverse lncRNA characteristics support a complex landscape of
RNA biology that remains largely unexplored in cardiovascular biology
and in particular heart failure [10].
Initially, lncRNAs have been classiﬁed according to their location
on the genome and orientation as compared to the closest coding
gene. Intergenic lncRNAs are located in between two coding genes,
not overlapping therefore with any coding sequences. They are usually
referred to as long intergenic (or intervening) noncoding RNAs
(lincRNAs). Enhancer-associated lncRNAs represent a subclass ofintergenic lncRNAs. In contrast, intragenic lncRNAs overlapwith coding
genes. In this case, lncRNAs can be transcribed from the sense or anti-
sense strand. Natural antisense transcripts (NATs) have been deﬁned
as overlapping antisense noncoding RNAs that regulate the expression
of their opposite coding gene. Finally, bidirectional noncoding RNAs
are transcribed at the close vicinity of a protein coding gene on the op-
posite strand. It is important to note that the subgroup of intergenic
lncRNAs has been studied in priority since data are easier to interpret
than those of overlapping lncRNAs. For a more detailed description of
lncRNA biogenesis, evolutionary history, structure and function, we
refer the readers to the recently published reviews [11–13].
Studies within the cardiovascular system are implicating lncRNAs as
important transcriptional regulators of cardiac gene expression at the
transcriptional and post transcriptional level. Table 1 lists a series of
recently identiﬁed cardiovascular lncRNAs. Typically, lncRNAs exhibit
distinctive roles in modulating tissue-speciﬁc epigenomic states and
nuclear organization, which are critical for the transcriptional and epi-
genetic reprogramming that underpinsHFpathogenesis [14]. The global
reorganization of the nuclear architecture and epigenome is indeed
central for the genome-wide transcriptional reprogramming that
underpins pathological remodeling. Numerous characteristics render
lncRNAs ideal molecules to provide cardiovascular cells with a catalog
of molecular address codes to guide transcriptional and epigenetic reg-
ulatory events in the genome [15]. For instance, an important character-
istic associated with lncRNAs in the cardiovascular system is that they
exhibit richer tissue and cell speciﬁcity when compared to mRNAs and
miRNAs [16,17]. These data suggest that an important function for
lncRNAs is to dictate combinations of ubiquitously expressed chromatin
modifying protein complexes in a highly cell speciﬁc manner. This
allows the establishment of tissue-speciﬁc epigenomic states that deter-
mine cellular fate and behavior post stress. A canonical example is
Myheart (Mhrt), a lncRNA encoded within the myosin heavy gene 7
(Myh7) locus [18]. This heart-enriched lncRNA is required formaintain-
ing cardiac function in the stressed heart, and its stress-dependent re-
pression leads to cardiomyopathy. Importantly, forced expression of
Mhrt is sufﬁcient to protect the heart from cardiac hypertrophy and sub-
sequent contractile failure. At the molecular level, Mhrt controls the
local epigenetic environment by acting as amolecular decoy and antag-
onizing the activity of Brg1, a chromatin remodeling factor known to be
important for the transcriptional reprogramming that occurs in the fail-
ing heart. Interestingly, human MHRT is also depleted in patients
suffering with cardiomyopathy, supporting a conserved role through
evolution.
Furthermore, lncRNAs can efﬁciently and rapidly operate both in cis,
at their site of transcription, and in trans at remote locations around the
genome. For example, a class of lncRNAs derived from developmental
and adult cardiac enhancers activates neighboring genes in cis via
DNA looping and pause release mechanisms [14,19]. A signiﬁcant
group of lncRNAs, typically associated with canonical active promoter
chromatin marks, act primarily in trans as recruiters or decoys for chro-
matin remodeling complexes and transcription factors to silence or ac-
tivate speciﬁc gene expression programs [20]. These functions are as a
consequence of a particularly high afﬁnity of lncRNAs for RNA binding
proteins such as components of the Trithorax (e.g. Fendrr) [21] and
Polycomb complexes (e.g. Bvht) [22]. Other trans-acting cardiovascular
lncRNAs have been shown to function as sponges for miRNAs, titrating
the ability of these small ncRNAs away from their sites of action [23].
Furthermore, lncRNAs can also regulate mRNA splicing, translation or
degradation through association with mRNAs or protein components
of RNP complexes. Therefore, it is becoming increasingly evident that
cardiovascular lncRNAs have functions in a diverse array of gene regula-
tory processes. However the ﬁeld is still in its infancy and it is impera-
tive that we develop a logical and ﬂexible approach for discovery and
annotation of high priority lncRNAs. This should foster their functional
and mechanistic exploration in the context of cardiovascular disease.
In this review, we summarize, discuss and propose best practices
Table 1
Cardiovascular lncRNAs.
LncRNA Species Biotype Function; association with disease Mechanism Ref.
ALIEN Human Intergenic Cardiovascular commitment Unknown [25]
ANRIL Human Antisense Metabolism; coronary artery disease Unknown [58]
HIF1A-AS2 Human Antisense Heart failure Unknown [59]
KCNQ1OT1 Human Antisense Cardiovascular development; arrhythmia Guide [60]
LIPCAR Human Unknown Heart failure Unknown [39]
MIAT Human Intergenic Myocardial infarction Decoy [61]
MYL4-AS Human Antisense Cardiac hypertrophy Unknown [62]
PUNISHER Human Antisense Endothelial cell identity Unknown [25]
SENCR Human Antisense Smooth muscle contractility Decoy [26]
TERMINATOR Human Intergenic Pluripotency; cardiovascular development Unknown [25]
Bvht Mouse Intergenic Cardiac mesoderm commitment Decoy [22]
Carl Mouse Intergenic Mitochondria; cardiomyocyte apoptosis Decoy [46]
Chrf Mouse Intergenic Cardiac hypertrophy Decoy [23]
Fendrr Mouse Intergenic Cardiac development Guide [21]
Malat1 Mouse Intergenic Endothelial cell identity Decoy [47]
Mhrt Mouse Intergenic Cardiac hypertrophy Decoy [18]
mm85 Mouse Intergenic Enhancer-associated lncRNA Cis-regulation [19]
Novlnc6 Mouse Intergenic Enhancer-associated lncRNA Unknown [16]
Smad7-lncRNA Mouse Antisense Enhancer-associated lncRNA Cis-regulation [19]
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for the discovery and characterization of cardiovascular lncRNAs.
Exploring this uncharted territory has wide ranging implications for
our understanding of cardiovascular biology and disease, representing
a potential treasure trove of speciﬁc and efﬁcient therapeutic targets
for the amelioration of heart disease.
3. Discovery of cardiovascular lncRNAs
Gene expression proﬁlingwithin the cardiovascular system typically
utilizes the powerful approaches of massively parallel RNA sequencing
(RNA-Seq). The pervasive nature of these approaches has recently
led to an avalanche of data on cardiovascular transcriptional units,
complexity and isoforms in a number of cardiovascular contexts [7].
RNA-Seq has now been used for a number of cardiovascular cell types,
including cardiovascular precursor cells, cardiomyocytes, endothelial
cells and vascular smooth muscle cells during differentiation andmatu-
ration, development and in adulthood including models such as myo-
cardial infarction and pressure overload (Table 1) [16,19,24–28]. The
ﬁrst step in the analysis process is to assemble transcripts from the se-
quence reads. Classically, this step involves ﬁrst mapping of the se-
quence reads to a reference genome and then assembling the
transcripts based on the genomic coordinates using tools such as
Cufﬂinks [29] or Scripture [30]. An alternative strategy is to perform tran-
script assembly directly from the sequence reads without the need of a
reference genome (e.g. Oases [31], Trinity [32]). The latter strategy is
necessary when no reference genome is available, or the reference ge-
nome is of poor quality. In our work, since we focus on identiﬁcation
of lncRNAs in mouse and human for which the genome sequences are
well annotated, we have used a classical approach of ﬁrst mapping
RNA-Seq reads to the genome and then performing ab initio transcript
reconstruction using the Cufﬂinks algorithm [16,19]. A workﬂow sum-
marizing our lncRNA discovery pipeline is shown in Fig. 1. We start
from three or more samples of polyA+ mRNA and sequence to a
depth of 200–400million 100nt paired-end reads. At least three biolog-
ical replicates per condition are necessary to enable any meaningful
downstream statistical comparisons. It is favorable to sequence as
many replicates as possible to gain enough power to detect differences
genome-wide. The number of samples requiredwill depend strongly on
the biological and technical variability of an experiment. In our experi-
ence, we have found that, for exploratory analyses of homogeneous
samples (e.g. cell lines, tissues from genetic mouse mutants and
controls) in a highly controlled experiment, three biological replicates
at high read depth can provide on the onehand sufﬁcient reads to detect
novel lncRNAs, and on the other sufﬁcient power to detect statisticaldifferences between conditions. Of course, in a realworld setting involv-
ing theuse of clinical subjects,manymore sampleswould be required to
achieve a similar statistical power. Following transcript assembly from
mapped sequence reads, the next step in our pipeline is tomerge the re-
sults of the ab initio transcript predictionwith known transcripts from a
high quality database of known transcripts such as Ensembl [33]. This in-
volves a comparison of the genomic coordinates of the RNA-Seq-
generated transcripts with those of the reference transcripts, creating
a single GTF (Gene Transfer Format) ﬁle containing all known and
novel transcripts. This is performed using Cuffmerge, which is part of
the Cufﬂinks package [29]. Using the information gained from known
transcripts it is possible to now divide the transcripts into known and
novel. Of course, at this stage, both protein-coding and noncoding tran-
scripts are represented. It is therefore necessary to separate these tran-
scripts using appropriate computational tools. Such tools can be divided
into conservation-based (CSF and PhyloCSF [34]), which rely on evolu-
tionary conservation of coding sequences to test whether a particular
transcript is coding, and non-conservation based (CPC [35], CPAT [36],
GeneID [37]), which rely on sequence feature-based classiﬁers. The
former conservation-based methods are limited in that they will only
reliably detect coding regions from known protein families, and not re-
cently evolved protein coding genes. The latter non-conservation based
methods are based on training classiﬁers to recognize particular fea-
tures of coding sequences. These latter methods have the advantage
that they do not require a sequence to be conserved across species to
predict that it would be coding, only that the sequence shares some fea-
tures with most coding sequences. Such machine learning approaches
however often suffer from high type 1 (false positive) and type 2
(false negative) error rates, and can behave better or worse depending
on whether the dataset being tested is similar to the data used to train
the algorithmor not. In our pipeline, weﬁlter thenovel transcripts to re-
move those that contain a single exon or are below 200nt in length
(these are the current accepted standards to deﬁne a lncRNA), and
then use GeneID to score novel transcripts for their coding potential.
Novel single-exon transcripts are removed because this subgroup is
more likely to be contaminated with artifacts due to fragments pro-
duced during RNA-Seq. In order to deﬁne an appropriate score cutoff
to optimally separate coding andnoncoding transcripts,we recommend
ﬁrst running GeneID on all the known coding and noncoding transcripts
for a given experiment, and plotting the score distributions of known
coding versus noncoding transcripts. In our example from myocardial
lncRNAs the coding score cutoff was taken at the intersection of the
known coding and noncoding score distributions (Fig. 1).
In our experience, paired-end sequencing to a depth of at least 300
million reads is essential to detect novel tissue-speciﬁc lncRNAs [16].
Fig. 1. Pipeline for the discovery and annotation of cardiovascular lncRNAs. See text for details. Images are reproduced with permission from Ounzain et al. EHJ. 2015 (Ref. [13]).
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cently able to identify 1500 novel multi-exonic polyadenylated lncRNAs
in the infarcted myocardium [16], and 2500 from mouse embryonic
stem (ES) cell differentiating towards cardiomyocytes [19]. In order to
test how important depth was in our discovery efforts, we performed
a simulation in which we counted how many novel lncRNAs would
have been discovered at increasing sequencing depths (Fig. 2; see leg-
end for details). Our results are striking: If we had sequenced to a typicaldepth of 50 million paired-end reads, we would have missed 50–60% of
the novel lncRNAs. It is important to emphasize again that the novel
lncRNAs that required the greatest depth of sequencing for discovery
were those exhibiting the most interesting functional and regulatory
characteristics linked to cardiovascular cell function and biology [16].
In contrast, we have found that shallow sequencing will lead to the
identiﬁcation of mainly annotated, non tissue-speciﬁc lncRNAs. Based
on this computational simulation, we suggest therefore that samples
Fig. 2. Numbers of novel lncRNAs discovered at different read depths in adult heart and ES cells. Starting from the total reads in a dataset, 10 million reads were removed from the data
iteratively, and the raw counts per genewere adjusted to the new total number of reads, bymultiplying the counts by the proportion of total reads in the sample. An average per genewas
then taken across all samples, and only those genes that passed our minimum threshold for expression were kept (mean counts ≥ 5) and plotted against read depth. For both the adult
heart and ES cell experiments, the slope is steeper at lower read depths (up to 50 million reads), and tails off gradually at higher depths. Fifty million reads is the depth typically used
in RNA-Seq experiments. The blue-boxed area highlights the numbers of lncRNAs that would be discovered using this standard read depth and below. The green-boxed area highlights
the numbers of novel lncRNA that would be ‘missed’when sequencing to this standard depth. Above 100 million reads, there is a steady increase in number of novel lncRNAs discovered
as read depth increases, with no plateau reached even at read depths of 400million and over. Based on this analysis, we predict that a plateauwill be reached between 500 and 600million
reads per sample. We recommend sequencing to a depth of at least 350 million reads, which we predict will allow detection of the vast majority of novel lncRNAs in a sample.
21S. Ounzain et al. / Journal of Molecular and Cellular Cardiology 89 (2015) 17–26should be sequenced at a depth of at least 350million readswith amin-
imum of three biological replicates. In addition, the size of paired-end
reads, i.e. 100 base pairs, is essential to facilitate transcriptome assembly
and allow isoform resolution of both mRNAs and lncRNAs.
4. Functional annotation of cardiovascular lncRNAs
Once novel lncRNAs have been identiﬁed and computationally
demonstrated to lack coding potential, candidates can be prioritized
for functional characterization based on a number of criteria including,
(a) tissue- and cell type-speciﬁc expression; (b) cytoplasmic vs. nuclear
expression; (c) dynamic response to developmental or environmental
cues; (d) guilt-by-association analysis, i.e. analysis of co-expression with
coding genes of functional relevance; (e) correlated expression with car-
diovascular physiological traits and parameters; (f) association with spe-
ciﬁc chromatin states; (g) inferred functions based on developmental
chromatin state patterns and (h) the possible existence of a human
ortholog [16]. To assess cell and tissue speciﬁcity, we recommend
quantifying expression of newly identiﬁed lncRNAs in publicly available
RNA-Seq datasets (e.g. ENCODE data). It is then possible to determine
the relative expression of candidate lncRNAs in the tissue of interest, in
this case heart, versus the mean expression in all non-cardiac tissues.
This then allows heart speciﬁcity of new lncRNAs to be determined and
interpreted. Not surprisingly, using comparable approaches, a number
of studies have demonstrated that typically novel lncRNAs identiﬁed
within the heart exhibit much greater cardiac speciﬁcity than protein
coding genes and even miRNAs [16,17]. These ﬁndings do not rule outthat lncRNAs demonstrating more global expression pattern are not im-
portant for cardiac development andhomeostasis. However,with regards
to their therapeutic potential, heart-enriched lncRNAs represent ideal
candidates since targeting these lncRNAs should minimize off-target
effects.
As already mentioned above, many lncRNAs can remodel their local
chromatin environment to regulate the expression of nearby develop-
mental and physiological coding genes in cis to control homeostasis.
Therefore, using a guilt-by-association approach to analyze the expres-
sion patterns of proximal coding genes represents a powerful way to
identify functionally important cis-regulatory lncRNAs. Furthermore,
lncRNAs whose expression kinetics are highly correlated with function-
ally important networks of coding genes during development or patho-
logical remodeling also suggests such lncRNAs may be functionally
involved in parallel processes. Depending on the cell type and tissue ex-
amined, this correlative approach can be expanded to identify lncRNAs
highly correlated with physiological traits and characteristics. The
unique nature of RNA-Seq approaches lend global lncRNA expression
data amenable to direct correlation proﬁling with continuous physio-
logical traits of choice. This is of particular relevance within the heart,
an organ that can be physiologically assessed using non invasive
methods including echocardiography to evaluate cardiac dimensions
and function. For example, we and others have correlated lncRNA ex-
pression proﬁles with echocardiography derived physiological traits
[16,17]. Impressively, novel lncRNAs were better correlated with cardi-
ac traits when compared to mRNAs and miRNAs. Such an approach
allows the ﬁltering of lncRNAs predicted to be relevant in very speciﬁc
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marker perspective, this type of approach also demonstrates that unsu-
pervised clustering of lncRNAs is able to distinguish physiological traits.
It indicates that lncRNAs could represent highly speciﬁc indicators of
physiological traits, with signiﬁcant diagnostic and prognostic values
in a clinical setting. Supporting this observation, recent investigations
have supported the presence of lncRNAs in the blood. These molecules
could aid in the diagnosis and prognosis of cardiovascular disease
[38–40].
An increasingly powerful approach for the functional and regulatory
annotation of novel lncRNAs is to characterize their underlying chroma-
tin states in relevant tissue, cell types and pathological situations using
publicly available and in house-generated ChIP-Seq data sets. Chroma-
tin maps have previously been used for the initial identiﬁcation of the
intergenic class of long noncoding transcripts (lincRNAs), which were
identiﬁed on the basis of their association with a canonical promoter
signature (H3K4me3) at their transcriptional start sites. These
intergenic lncRNAs typically encode trans-regulatory functions, regulat-
ing global transcriptional programs of numerous coding genes across
chromosomes. Alternatively, a large fraction of newly identiﬁed
lncRNAs, particularly in the heart, are derived from active tissue-
speciﬁc enhancers characterized by H3K4me1 and H3K27Ac occupancy
[16]. Enhancer-associated lncRNAs typically regulate their target coding
genes in cis. Importantly, a number of studies have implicated theseFig. 3. Functional inference of novel cardiovascular lncRNAs based on chromatin state transitio
derived from ChIP-Seq data sets obtained in differentiating mouse ES cells (see Ref. [24]), it isenhancer-associated lncRNAs as being functionally required for enhanc-
er activity via mediating chromatin looping, promoter enhancer
communication and Pol2 pause-release at target promoters [14]. We
and others have identiﬁed hundreds of cardiac enhancer-associated
lncRNAs that are involved in the global heart-speciﬁc enhancer-
dependant cis-regulation of transcriptional programs, which underpin
cardiac development and pathological remodeling. Supporting this,
the proximal coding genes to these transcribed novel enhancer-
associated lncRNAs are in general implicated in heart development
and cardiac homeostasis. Moreover, enhancer-associated lncRNA
expression in the injured heart usually correlates with coding gene
expression [19].
Integration of chromatin state patterns and dynamics can also be
leveraged for inferring functions for novel lncRNAs. This in particular
pertains to chromatin state patterns associated with coding gene pro-
grams during cardiac differentiation. It has previously been shown
that lineage-speciﬁc coding genes in differentiating cells cannot be
assigned to a particular function based on their expression pattern
alone. However, lineage-speciﬁc coding genes that are co-expressed at
particular stages can be functionally grouped based on their distinct
chromatin state patterns at their promoters during cardiac differentia-
tion [24]. In other words, subgroups of co-expressed genes, clustered
based on unique chromatin state patterns, appeared to be involved in
highly specialized and distinct biological processes, including signaling,n during cardiogenic differentiation. Using common patterns of chromatin state transition
possible to infer functions for novel cardiovascular lncRNAs.
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tion, one can assume that novel cardiovascular lncRNAs that shared
comparable chromatin state patterns as those observed at coding
genes, are likely to be involved in parallel biological processes. This ap-
proach provides a powerful unbiased chromatin-based proxy to infer
functions and annotate novel cardiovascular lncRNAs. Using this ap-
proach, we found that heart-enriched lncRNAs identiﬁed in the infarct-
ed myocardium were preferentially assigned to chromatin pattern
clusters linked to specialized cardiac-speciﬁc processes, including
heart development and contractility [16]. In addition, the novel
lncRNAs, which, as described above, were identiﬁed using greater RNA
sequencing depth, were more associated with these cardiac functional
processes than annotatedmRNAs and lncRNAs. These ﬁndings give fur-
ther support to the relevance of the low-abundance lncRNAs for cardiac
physiology. Inferring function during cardiogenic differentiation in ES
cells makes possible the identiﬁcation of novel lncRNAs that are expect-
ed to play signiﬁcant roles in the adult heart.Moreover, this analysis can
predict the functional processes that may be perturbed in vivo when
experimental modulation of the lncRNA of interest is performed.
Upon completion of the integrated genomic approaches, it is impor-
tant to identify human orthologs. This can be achieved directly by utiliz-
ing human heart RNA Seq data sets and mapping the lncRNA catalog to
the human genome using TransMap, a cross species transcript align-
ment tool [41]. TransMap will map murine cardiovascular lncRNAs
across the human genome using syntenic BLASTZ alignments that con-
sider gene order and synteny. Furthermore, TransMap can integrate
RNA sequencing reads from human samples to reﬁne and complete
ortholog identiﬁcation and annotation. Finally, once orthologous
human lncRNAs have been identiﬁed, it is possible to assess human
lncRNA expression in human RNA Seq datasets, including those gener-
ated by large scale consortia such as the ENCODE [42] and Gtex consor-
tiums [43]. It is also possible tomap single nucleotide variants identiﬁed
in genomewide association studies (GWAS) and linked to common car-
diovascular traits and disease with orthologous lncRNA loci. This ap-
proach is likely to provide clues to the potential functions of identiﬁed
cardiovascular lncRNAs. The ﬁrst evidence for a putative role of lncRNAs
in cardiovascular diseases came from a GWAS that identiﬁed a suscepti-
bility locus for coronary artery disease on the human chromosome 9p21Fig. 4. Different approaches for the functional assessment of lncRNAs in vitro and in vivo. Gain
classical genetic models can be adopted in vivo and in vitro to assess novel cardiovascular lncR
be analyzed using various techniques and physiological models.[44]. This locus is in linkage disequilibrium with a lncRNA named anti-
sense noncoding RNA in the INK4 locus (ANRIL) suggesting that single
nucleotide variants within ANRIL could contribute to susceptibility for
the development of coronary artery disease. Indeed, a number of
follow-up studies have demonstrated that ANRIL expression is indica-
tive of a risk for peripheral artery disease, carotid atherosclerosis, coro-
nary atherosclerosis and other vascular diseases [45].
5. Functional assessment of cardiovascular lncRNAs
Prior to functional dissection, it is imperative that candidate lncRNA
expression proﬁles are validated by quantitative methods including
RT-PCR in relevant tissue samples and possibly in isolated primary
cells, to gauge expression levels and tissue and cellular speciﬁcity.More-
over, in situ hybridization can be executed on appropriate histological
tissue sections to conﬁrm expression data. To better understand the
physiological roles of cardiovascular lncRNAs during development and
disease, and to decipher whether their regulatory functions operate
via cis or trans mechanisms generally requires experimental modula-
tion of lncRNA expression. These include in vitro and in vivo gain- and
loss-of-function approaches (Fig. 4). Initially, cardiovascular lncRNA
knockdown has been performed using RNA interference, such as small
interfering (siRNA) or small hairpin RNAs (shRNA), followed by molec-
ular and cellular analysis to determine the global effects on gene expres-
sion and cellular behavior. In a seminal study, this approachwas used to
identify and characterize a lncRNA important for cardiac speciﬁcation,
which was named Braveheart (Bvht) [22]. Transducing mouse ES cells
with shRNAs to deplete Bvht led to impaired cardiogenic differentiation
in vitro. Through transcriptomic analysis, it was shown that Bvht acts
upstream of the key cardiogenic TF, Mesp1, to induce its expression
and direct correct temporal and spatial activation of the subsequent
cardiac gene regulatory network. A similar approach was used for the
characterization of previously unannotated human vascular lncRNAs,
TERMINATOR,ALIEN and PUNISHER [25]. These lncRNAswere speciﬁcally
expressed in pluripotent stem cells, cardiovascular progenitors and dif-
ferentiated endothelial cells. Loss of function using shRNAs in vitro and
antisense morpholino nucleotides against zebraﬁsh orthologs in vivo
demonstrated that all three lncRNAs are involved in vertebrate- and loss-of-function approaches using shRNAs, modiﬁed antisense oligonucleotides and
NA function. Once manipulated, downstream genomic and functional consequences can
24 S. Ounzain et al. / Journal of Molecular and Cellular Cardiology 89 (2015) 17–26cardiovascular development. In addition to endothelial cells, siRNA ap-
proaches have also been successfully adopted in smooth muscle cells
(SMCs). For example, siRNA mediated knockdown of the SMC lncRNA
SENCR results in deregulation of a SMC-speciﬁc gene, namely MYOCD,
which is a critical co-factor responsible for dictating the SMC gene pro-
gram [26]. Finally, shRNA was also used to deplete the cardiomyocyte-
enriched lncRNA, Carl. This lncRNA acts as a competitive endogenous
RNA (ceRNA) for miR-534, which regulates mitochondrial ﬁssion and
cardiomyocyte apoptosis [46].
Despite the success of RNA interference strategies, concerns have
been raised about the efﬁcacy of these techniques for depleting nuclear,
and in particular, enhancer-associated lncRNAs. Indeed, the machinery
used by the RNA interference pathway is predominantly enrichedwith-
in the cytoplasm. To overcome these obstacles, and allow targeting of
nuclear-enriched cardiovascular lncRNAs, many investigators are utiliz-
ing modiﬁed antisense oligonucleotides (ASOs), called LNA GapmeRs.
Importantly, GapmeRs degrade transcripts in the nuclear compartment
via a RNaseH-dependent mechanism, leading to efﬁcient depletion of
nascent transcripts. This has proven to be particularly efﬁcient for the
depletion of cardiac enhancer-associated lncRNAs in cardiomyocytes
(e.g. Novlnc6), cardiac ﬁbroblasts (e.g. Smad7-lncRNA) and cardiac
precursor cells (e.g. mm85) [16,19]. Therefore, LNA GapmeR-mediated
depletion of these enhancer-associated cardiovascular lncRNAs results
in perturbed expression of the target coding genes. GapmeRs also
offer a powerful approach for depleting lncRNAs in vivo. Malat1 is a
lncRNA predominantly enriched in the nucleus and highly responsive
to hypoxia in human umbilical vein endothelial cells. Inhibition of
Malat1 in vivo using LNA GapmeRs impaired vascularization of the ret-
ina and ischemic hind limb [47]. This identiﬁes this transcript as an in-
teresting cardiovascular target to promote or block angiogenesis. More
generally, involvement of candidate lncRNAs in speciﬁc biological pro-
cesses can be evaluated in large-scale assays based on the unbiased
screening of large collections of GapmeRs in relevant cell types using
high-resolution techniques.
In addition to using RNA interference and modiﬁed antisense oligo-
nucleotide approaches, genome editing technologies can be used to
modify cardiovascular lncRNA expression in vivo. Classical approach
via generating transgenic knockouts, either germline or conditional
knockouts, can be envisaged. However, we are facing two main con-
strains. First of all, deletion of lncRNA gene overlapping a coding gene
might be largely uninformative due to possible interference with natu-
ral expression of the coding RNA. Second, deletion of any given DNA
sequence to eliminate the corresponding lncRNAmight produce a phe-
notype solely because a mutation is introduced in a functional DNA ele-
ment. In a prominent study, the depletion of Fendrr was therefore
obtained by inserting a premature transcription stop signal into the
ﬁrst exon [21]. This resulted in embryonic lethality as a consequence
of impaired cardiac development and body wall formation. Mechanisti-
cally, Fendrr orchestrates epigenomic states critical for cardiovascular
cell speciﬁcation and differentiation. Using a different genetic approach,
the Fendrr locuswas replaced by the LacZ reporter gene, resulting also in
embryonic lethality, however much later during development [48].
Follow-up studies suggested that Fendrr loss of function led to defects
in lung maturation and vascularization. In the future, the lncRNA ﬁeld
will certainly beneﬁt from new techniques to generate targeted muta-
tions in the genome, such as the TALEN and Cas9/CRISPR systems.
Transgenic approaches for gain-of-function studies have also gained
traction and illuminated roles for newly described lncRNAs. As de-
scribed earlier, Mhrt is an antisense transcript to the Myh7 locus and
was recently shown to interfere with cardiac hypertrophy and subse-
quent development of heart failure. This was formally demonstrated
using a transgenic approach for restoring normal Mhrt levels in the
stressed heart, which blunted the switch from Myh6 to 7 expression
and protected the heart from pathological remodeling [18]. This effect
wasmediated by the binding ofMhrt to the Brg1/Baf chromatin remod-
eling complex, titrating it away from its target genomic loci. Althoughgain-of-function approaches reveal important trans-dependent regula-
tory roles for cardiovascular lncRNAs, loss-of-function approaches cur-
rently represent the most biologically relevant strategy to investigate
underlying molecular mechanisms. First of all, many lncRNAs act in a
dose-dependent manner when binding ubiquitously expressed chro-
matin modifying protein complexes. As such, overexpression of candi-
date cardiovascular lncRNAs could lead to spurious effects through
dominant-negative actions. Speciﬁcally, supra physiological lncRNA
expression could titrate important chromatin modifying complexes
away from their natural genomic sites of action, leading to unpredict-
able effects. Finally, a large fraction of newly discovered cardiovascular
lncRNAs act as regulators of the epigenome and nuclear architecture
in cis at their site of production. In particular, the regulatory function
of lncRNAs derived from active enhancers act primarily at their endog-
enous site of production. Therefore, modulation of the nascent tran-
script is critical and exogenous overexpression is not a viable option.6. Mechanistic assessment of cardiovascular lncRNAs
Complete characterization of cardiovascular lncRNAs requires a de-
tailed knowledge of themolecularmechanisms associated to their func-
tion. Two recently developed techniques provide a means to assess
when and where lncRNAs are binding and acting within the genome.
These comparable techniques, namely chromatin isolation by RNA puri-
ﬁcation (ChIRP) [49] and capture hybridization analysis of RNA targets
(CHART) [50], are able to map the genomic binding sites of endogenous
lncRNAs. CHART uses cocktails of several short, complementary and af-
ﬁnity tagged oligonucleotides. These complimentary oligonucleotides
allow speciﬁc enrichment for endogenous lncRNAs, along with their ge-
nomic DNA targets from reversibly crosslinked chromatin extracts,
which can be sequenced to identify genome-wide binding sites. Similar-
ly, lncRNA-binding proteins can be identiﬁed by CHARTmass spectrom-
etry. ChIRP also hybridizes biotinylated complimentary oligonucleotides
to crosslink chromatin, although in this case tiling oligonucleotides are
used, which require no previous knowledge of lncRNA structural do-
mains. ChIRP can also be combinedwithDNA sequencing andmass spec-
trometric approaches to identify genomewide binding sites and protein
partners.
Not all cardiovascular lncRNAs interact with chromatin but the vast
majority of functional lncRNAs bind to and recruit protein complexes.
The identiﬁcation of the lncRNA interactome is thus critical for a com-
plete understanding of cardiovascular lncRNA function. A conventional
approach to address this question relies on the use of RNA chromatog-
raphy [51]. Here, one can use afﬁnity tagged oligonucleotides spanning
the lncRNA of interest as baits on which interacting proteins can
assemble. Interacting proteins are then eluted and analyzed by mass
spectrometry (MS). Once potential interacting protein partners have
been identiﬁed, classical approaches can be used including RNA-
immunoprecipitation assays followed by qRT-PCR to validate such in-
teraction. However, this classical approach can often generate false pos-
itives due to promiscuous binding of proteins to the oligonucleotide
baits. Direct capture of endogenous lncRNAs using antisense oligonucle-
otide probes aswith ChIRP and CHARTMS can reinforce the relevance of
the identiﬁed proteins. For instance, puriﬁcation of endogenous
interacting partners has been demonstrated for the human telomerase
RNA TERC and the miRNA let-7 [52,53]. However, a major challenge is
that proteins, unlikeDNA or RNA, cannot be ampliﬁed for further valida-
tion. This places an experimental constraint on the amount of material
required for in vivo puriﬁcation due to the lower copy number of
lncRNAs. Newly developed technologies, including protein arrays, can
be used to screen RNA binding proteins without the obvious constraint
in startingmaterial. Microscale devices containing proteins printed on a
solid support, allow the binding of synthesized RNAs containing a ﬂuo-
rescent label [54,55]. Following speciﬁc binding to proteins, the array
will illuminate their corresponding coordinates. This can be imaged in
25S. Ounzain et al. / Journal of Molecular and Cellular Cardiology 89 (2015) 17–26a similarway to nucleic acidmicroarrays and interacting proteins can be
identiﬁed in a high throughput manner.
In addition to proteins, lncRNAs can also interact with RNA cofactors.
RNA interactions can be assayed by hybridization techniques, including
ChIRP. Using this approach bound RNAs are eluted and subjected to RNA
sequencing or quantitative RT-PCR. Investigators have demonstrated that
a lncRNA named TINCR, known to control epidermis differentiation, inter-
acts withmRNAs implicated in skin development, impacting their expres-
sion [56]. Alternative methods use alternative crosslinking approaches, in
particular UV light, which are able to capture only hybridizing RNAmole-
cules. For example, crosslinking, ligation and sequencing of hybrids
(CLASH) has been successfully used to examine direct RNA pairing be-
tweenmiRNAs and their targetmRNAs, and can be envisaged for lncRNAs
in the not too distant future [57].
7. Conclusion
We are entering a new era where we are beginning to understand
the complex roles of cardiovascular lncRNAs during development and
disease. This highly integrated and complex layer of regulatory noncod-
ing RNAs exhibits dynamic interplay with components of various pro-
tein complexes to dictate the activity of the cardiac gene regulatory
network. Cardiac pathological states, including heart failure, are inti-
mately linked to the dynamics of cardiovascular lncRNA expression
and regulatory functions. To increase our understanding and potentially
identify new avenues for therapeutic intervention, the full extent of the
cardiovascular lncRNA transcriptome needs to be determined and cor-
rectly annotated. This needs to be executed at different stages of cardiac
development and during disease. Genomic approaches should in the fu-
ture also interrogate the non-polyadenylated and single exon RNA frac-
tion (i.e. eRNAs). This should open up new insights into the biology of
cardiovascular cells, and hopefully will identify new players in the reg-
ulatory network governing cardiac development and homeostasis. Of
critical importance is that investigators discovering new cardiovascular
lncRNAs leverage the plethora of new approaches to decipher the lan-
guage used by lncRNAs to interact with their respective protein or
RNA partners. This should illuminate our understanding of these still
elusive but potentially exciting therapeutic targets.
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